Low-Dose Atropine Treatment Slows Pediatric Myopia Progression

TUESDAY, June 6, 2023 (HealthDay News) -- Low-dose atropine treatment reduces pediatric myopia progression compared with placebo over three years of treatment, according to a study published online June 1 in JAMA Ophthalmology.
Karla Zadnik, O.D., Ph.D., from The Ohio State University in Columbus, and colleagues assessed the safety and efficacy of NVK002, a novel, preservative-free, once-daily 0.01 percent and 0.02 percent low-dose atropine formulation for treating myopia progression versus placebo. The analysis included 573 randomly assigned pediatric participants (aged 3 to 10 years in the safety group, of whom 489 children aged 6 to 10 years were in the modified intention-to-treat group), from 23 sites in North America and five countries in Europe. Participants had −0.50 diopter (D) to −6.00 D spherical equivalent refractive error (SER) and no worse than −1.50 D astigmatism.
The researchers found that compared with placebo, low-dose atropine (0.01 percent) significantly increased the responder proportion (odds ratio, 4.54; 95 percent confidence interval, 1.15 to 17.97; P = 0.03), slowed mean SER progression (least squares mean [LSM] difference, 0.24 D), and slowed axial elongation (LSM difference, −0.13 mm) at the three-year mark. While 0.02 percent dosage also showed benefit, it was not associated with a significant increase in the responder proportion (odds ratio, 1.77; 95 percent confidence interval, 0.50 to 6.26; P = 0.37) nor slowed mean SER progression (LSM difference, 0.10 D), but it did slow mean axial elongation (LSM difference, −0.08 mm). Atropine was not associated with any serious ocular adverse events.
"Trial results show that the efficacy and safety observed may be supportive of a pharmacological treatment option for myopia progression in children," the authors write.
Several authors disclosed ties to ophthalmic-biopharmaceutical companies, including Vyluma, which manufactures NVK002 and funded the study.
Related Posts
Widening Gap ID’d in Housing Affordability for Resident Physicians
TUESDAY, June 27, 2023 (HealthDay News) -- Resident physicians face a widening...
Biden utiliza una máquina de PPCVR de noche para ayudar a aliviar la apnea del sueño
JUEVES, 29 de junio de 2023 (HealthDay News) -- El Presidente Joe Biden comenzó...
Las carreteras rurales de EE. UU.: tranquilas pero letales, encuentra un nuevo informe
MARTES, 6 de septiembre de 2022 (HealthDay News) -- Un nuevo informe revela un...
Consumir frutos secos a diario podría ayudar al corazón
MARTES, 21 de marzo de 2023 (HealthDay News) -- Una forma de reducir el riesgo...